Endo Pharmaceuticals

FTC Keeps Pressure On Wall Street, Refiles Suit Against Allergan, Others

Endo Pharmaceuticals, BioDelivery Sciences Present Promising Data On New Chronic Pain Management Product

Endo Pharmaceuticals has Everybody Interested as M&A Target

Endo Pharmaceuticals, BioDelivery Sciences Present Promising Data On New Chronic Pain Management Product

Endo Pharmaceuticals has Everybody Interested as M&A Target

Fifteen Health Care ETFs Trading Near 52-Week Highs

Twelve Health Care ETFs Trading Near 52-Week Highs

Fifteen Health Care ETFs Trading Near 52-Week Highs

Twelve Health Care ETFs Trading Near 52-Week Highs

Citi Maintains Buy on Endo Pharmaceuticals

Endo Announces Topline Results From Phase 2 Study

Endo Pharmaceuticals Recent News

Piper Jaffray Reiterates Neutral Rating, $44 PT on Endo Pharmaceuticals

J.P. Morgan Resumes Coverage of Endo Pharmaceuticals with Overweight and PT of $50

Citi Raises Endo Pharmaceuticals Estimates

Citi Comments On Endo Pharmaceuticals Price Target

Oppenheimer Comments On Endo Pharmaceuticals 1Q11 Results

Citigroup Raises PT On Endo Pharmaceuticals To $48

Stifel Nicolaus Summary

UPDATE: Oppenheimer Raises PT on Endo Pharmaceuticals to $48 (ENDP)

Oppenheimer Raises PT On Endo Pharmaceuticals To $48

Jefferies Maintains Buy on Endo Pharmaceuticals (ENDP)

Piper Jaffray Raises PT On Endo Pharmaceuticals To $40

JP Morgan On Endo Pharmaceuticals

Oppenheimer Maintains ENDP Rating, Estimates And PT

Goldman Sachs Analyzes Fortesta Gel Approval (ENDP)

Endo Pharmaceuticals Portfolio Should Benefit from Qualitest Acquisition (ENDP)

J.P. Morgan Resumes Coverage on Endo Pharmaceuticals (ENDP)

FDA Cancels Opana TR Panel, No Generics = No Risk For Endo

Endo Pharmaceuticals Focusing On Execution

Citigroup Releases Endo Pharmaceuticals Core Product Trends; Explains Price Target

Buy Rating For AAPL, ENDP